Medical/Pharmaceuticals
AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023
* Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment are to be showcased at the SITC 2023 Annual Meeting SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therap...
2023-11-01 21:08
1737
Jolly Good Inc. Establishes North American Subsidiary: Joint Development of Medical VR for "Apple Vision Pro" with U.S. Experts
~ First Phase: Joint Development of Chronic Pain VR with U.S. Chronic Pain Experts TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North Ame...
2023-11-01 21:00
1974
SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System
SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achievement for SIBIONICS, fac...
2023-11-01 20:28
3105
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunother...
2023-11-01 20:00
1532
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainlandChina. CStone to retain the rights to nofazinlimab outside mainland China. * This partnership will combine the strengths of CStone a...
2023-11-01 18:10
3354
AXA BetterMe Weekend concludes in high note, drawing over 12,000 participants
Two-day carnival inspires physical and mental well-being Allowing citizens to unwind and rejuvenate to become a BetterMe HONG KONG, Nov. 1, 2023 /PRNewswire/ -- AXA BetterMe Weekend, the iconic annual carnival hosted by AXA Hong Kong andMacau (AXA) on 28 and 29 October 2023, was a resounding succ...
2023-11-01 18:02
2103
Curocell Completes Korea's First Phase 2 Clinical Trial for Next-Generation CAR-T
* Anbal-cel targeting DLBCL completes phase 2 trial * Anticipation growing over Korea's first CAR-T therapy ahead of regulatory review * Commercial manufacturing scheduled in 2025 at Korea's only CAR-T GMP facility DAEJEON, South Korea, Nov. 1, 2023 /PRNewswire/ -- Curocell, South Korea ...
2023-11-01 16:23
1638
P&G Health commemorates World Diabetes Day 2023 with innovative AI-based Experiential Campaign #KnowtheSigns
* 1 in 2 Diabetics and 1 in 10 Pre-diabetics estimated to suffer from Peripheral Neuropathy * Vitamin B Deficiency affects quality of life of ~ 19% of all people with diabetes * #KnowtheSigns leverages Artificial Intelligence to make the invisible condition of Peripheral Neuropathy & Vitami...
2023-11-01 14:00
1970
Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%
Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research. MOUNTAIN VIEW, Calif., Nov. 1, 2023 /PRNewswire/ -- In a groundbreaking research paper titled"Reversal of Biological Age in Mult...
2023-11-01 09:14
1236
Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
LONDON, Nov. 1, 2023 /PRNewswire/ -- Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be ...
2023-11-01 09:05
1066
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2023-11-01 08:30
1563
Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.
WASHINGTON, Oct. 31, 2023 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, announced today at the American Society of Human Genetics (ASHG) Annual Meeting,Nov. 1-5, in Washington details on the commercial and technical momentum it has demonstrated in the last 10 months ...
2023-10-31 21:44
1633
88th CMEF Unveils Cutting-Edge Medical Breakthroughs in Shenzhen, Unleashing the Latest Medical Technologies and Solutions
SHENZHEN, China, Oct. 31, 2023 /PRNewswire/ -- The 88th China International Medical Equipment Fair (CMEF) officially kicks off onOctober 28 at the Shenzhen World Exhibition & Convention Center. The four-day tradeshow will feature over 10,000 products brought by over 4,000 exhibitors from more tha...
2023-10-31 21:34
2244
Lunit Joins as an Associate Partner with the World Economic Forum
- Lunit joins as an Associate Partner of the World Economic Forum, propelling global expansion and collaboration in the realm of AI-driven cancer care SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and th...
2023-10-31 21:00
1631
BioLineRx Entered Exclusive License Agreement to Motixafortide in Asia, Advised by MSQ Ventures
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- MSQ Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the deve...
2023-10-31 21:00
3294
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-31 20:30
1474
Meihua International Medical Technologies Co., Ltd. Establishes A Subsidiary Dedicated to Introducing International Patented Pharmaceuticals and Medical Device Technologies to China and Hainan Free Trade Port Boao Hope City
YANGZHOU, China, Oct. 31, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, announced today the establishme...
2023-10-31 20:00
2776
HOYA Vision Care Releases One-Year MiYOSMART European Study Results
Initial evidence-based findings of three-year study strongly supports MiYOSMART portfolio BANGKOK, Oct. 31, 2023 /PRNewswire/ -- HOYA Vision Care, committed to developing innovative solutions to address the growing problem of myopia progression in children, extended its research toEurope in an ...
2023-10-31 19:13
1775
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS
* FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy * Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic * Phase 1A clinical trial to initiate patient enrolment in 2024 * Phase 1A clinical trial will enroll patients with advanced Colorecta...
2023-10-31 19:00
1429
Select the Right Medical-Grade TPU：ICP DAS - BMP Launches a New TPU Series at COMPAMED & IPF Japan 2023
HSINCHU, Oct. 31, 2023 /PRNewswire/ -- ICP DAS – Biomedical Polymers, Asia's first medical-grade TPU (thermoplastic polyurethane) manufacturer and supplier, will be exhibiting at COMPAMED inGermany and IPF in Japan in November and December 2023. The company proudly presents its new Arothane™ ARP-...
2023-10-31 16:38
2057
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 293 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 291 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9284
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7761
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
6412
